Investigational drug · Phase 2
CB03-154
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Focal Epilepsy.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "CB03-154"
First trial start
2025
Aug 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CB03-154", any sponsor or status.
Conditions studied
As listed on its trial records.
- Focal Epilepsy
Approved drugs for the same conditions: Epilepsy and seizures · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "CB03-154" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingRecruiting
Shanghai Zhimeng Biopharma, Inc.Industry
NCT07082192 · 240 participants (planned) · Start Oct 30, 2025 · Primary completion Sep 30, 2027
Drug: Test drug CB03-154 5mg group; Test drug CB03-154 10mg group and 2 more · For: ALS (Amyotrophic Lateral Sclerosis)
Sites: Beijing, China
- A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal EpilepsyPivotal-lookingRecruiting
Shanghai Zhimeng Biopharma, Inc.Industry
NCT06612775 · 180 participants (planned) · Start Aug 14, 2024 · Primary completion Sep 2027
Drug: Test drug CB03-154 5mg group; Test drug CB03-154 10mg group and 2 more · For: Focal Epilepsy
Sites: Melbourne, Australia
Shanghai Zhimeng Biopharma, Inc.Industry
NCT07238868 · 144 participants (planned) · Start Aug 14, 2025 · Primary completion Jan 2029
Drug: CB03-154 · For: Focal Epilepsy
Sites: Melbourne, Australia
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy ParticipantsStatus unknown
Shanghai Zhimeng Biopharma, Inc.Industry
NCT05499260 · 70 participants (planned) · Start May 2, 2022 · Primary completion Mar 2, 2023
Drug: CB03-154; Placebo · For: Healthy Volunteers
Sites: Secaucus, New Jersey
Shanghai Zhimeng Biopharma, Inc.Industry
NCT05502549 · 56 participants · Start Nov 29, 2022 · Primary completion Nov 9, 2023
Drug: CB03-154; Placebo · For: Healthy Volunteers
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Focal Epilepsy
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- RAP-219Phase 35 trials
Rapport Therapeutics Inc. · Focal Epilepsy, Epilepsy, Focal Seizure
- Test drug CB03-154 groupPhase 32 trials
Shanghai Zhimeng Biopharma, Inc. · ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.